Cargando…

Different stages in drug development for muscle-invasive bladder cancer

Muscle-invasive bladder cancer (MIBC) is a highly aggressive disease. Despite optimal therapy, half of the patients will succumb to disease. This prognosis could not be improved over the last three decades. Therefore, MIBC is left behind from other cancers such as prostate, where novel treatment opt...

Descripción completa

Detalles Bibliográficos
Autores principales: Ineichen, Gallus Beatus, Röthlisberger, Raphael, Johner, Kevin Fabian, Seiler, Roland
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760381/
https://www.ncbi.nlm.nih.gov/pubmed/29354493
http://dx.doi.org/10.21037/tau.2017.11.22
_version_ 1783291357040738304
author Ineichen, Gallus Beatus
Röthlisberger, Raphael
Johner, Kevin Fabian
Seiler, Roland
author_facet Ineichen, Gallus Beatus
Röthlisberger, Raphael
Johner, Kevin Fabian
Seiler, Roland
author_sort Ineichen, Gallus Beatus
collection PubMed
description Muscle-invasive bladder cancer (MIBC) is a highly aggressive disease. Despite optimal therapy, half of the patients will succumb to disease. This prognosis could not be improved over the last three decades. Therefore, MIBC is left behind from other cancers such as prostate, where novel treatment options were discovered and improve patient outcomes. While being aware of the recent emerging evidence of checkpoint inhibition in MIBC, we aim to describe different stages of drug development in MIBC by using three specific targets. On the example of Her2 targeting, we aimed to indicate, that either a target is ineffective in MIBC or that the patient selection is insufficient. The first clinical trials using a pan fibroblast growth factor receptor (panFGFR) inhibitor to target the FGFR pathway showed promising results. Data of further trials are to be awaited before implementing these drugs into daily clinical practice. A large variety of novel agents are investigated in vitro and in vivo. On the example of a malaria protein, we aimed to discuss a treatment paradigm that is not dependent on pathway signaling and the genomic landscape of MIBC. The ultimate question still remains to be answered: How do we select the optimal treatment for the right patient?
format Online
Article
Text
id pubmed-5760381
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-57603812018-01-19 Different stages in drug development for muscle-invasive bladder cancer Ineichen, Gallus Beatus Röthlisberger, Raphael Johner, Kevin Fabian Seiler, Roland Transl Androl Urol Review Article Muscle-invasive bladder cancer (MIBC) is a highly aggressive disease. Despite optimal therapy, half of the patients will succumb to disease. This prognosis could not be improved over the last three decades. Therefore, MIBC is left behind from other cancers such as prostate, where novel treatment options were discovered and improve patient outcomes. While being aware of the recent emerging evidence of checkpoint inhibition in MIBC, we aim to describe different stages of drug development in MIBC by using three specific targets. On the example of Her2 targeting, we aimed to indicate, that either a target is ineffective in MIBC or that the patient selection is insufficient. The first clinical trials using a pan fibroblast growth factor receptor (panFGFR) inhibitor to target the FGFR pathway showed promising results. Data of further trials are to be awaited before implementing these drugs into daily clinical practice. A large variety of novel agents are investigated in vitro and in vivo. On the example of a malaria protein, we aimed to discuss a treatment paradigm that is not dependent on pathway signaling and the genomic landscape of MIBC. The ultimate question still remains to be answered: How do we select the optimal treatment for the right patient? AME Publishing Company 2017-12 /pmc/articles/PMC5760381/ /pubmed/29354493 http://dx.doi.org/10.21037/tau.2017.11.22 Text en 2017 Translational Andrology and Urology. All rights reserved.
spellingShingle Review Article
Ineichen, Gallus Beatus
Röthlisberger, Raphael
Johner, Kevin Fabian
Seiler, Roland
Different stages in drug development for muscle-invasive bladder cancer
title Different stages in drug development for muscle-invasive bladder cancer
title_full Different stages in drug development for muscle-invasive bladder cancer
title_fullStr Different stages in drug development for muscle-invasive bladder cancer
title_full_unstemmed Different stages in drug development for muscle-invasive bladder cancer
title_short Different stages in drug development for muscle-invasive bladder cancer
title_sort different stages in drug development for muscle-invasive bladder cancer
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5760381/
https://www.ncbi.nlm.nih.gov/pubmed/29354493
http://dx.doi.org/10.21037/tau.2017.11.22
work_keys_str_mv AT ineichengallusbeatus differentstagesindrugdevelopmentformuscleinvasivebladdercancer
AT rothlisbergerraphael differentstagesindrugdevelopmentformuscleinvasivebladdercancer
AT johnerkevinfabian differentstagesindrugdevelopmentformuscleinvasivebladdercancer
AT seilerroland differentstagesindrugdevelopmentformuscleinvasivebladdercancer